Replies to post #17219 on RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

interesting article, and highlight, thanks Aiming4

>>"We are working on glutamate receptor medicines for memory and cognition,” says Steve Paul, president of Lilly Research Laboratories. “This is a big future growth area for us.”<<

I wonder if Lilly underestimated Cor's staying power and growth potential. Just needed serendipity and agility to capture an off target indication. So what if RD was of necessity. Dr Greer partnered with Cor, not Lilly.

Will Lilly come courting Cor, with a different face, than the one they wore while liberating Cor European IP, in the name of expanding public access?